R&D | Cutting-edge science and innovative research

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

R&D

startup discussion investment ideas visual

Strategies for creating an ecosystem to support early-stage ...

Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations

News

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

News

Eikon, Veradermics close IPOs, as Salspera joins queue

Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.

News

Taiho snaps up ADC partner Araris for up to $1.14bn

Taiho has reached a deal to buy Swiss biotech Araris, around 18 months after they started collaborating on antibody-drug conjugates for cancer.

R&D

Sponsored

12 Questions with Alex Guillen

As Global SME of Life Science and Pharma at Tive, Alex Guillen leads sales and business development within the company's rapid-growth life sciences division.

News

AbbVie builds the case for ovarian cancer drug Elahere

AbbVie hopes for another lift to its fast-growing ovarian cancer drug Elahere with new survival data.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

News

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Strategies for creating an ecosystem to support early-stage ...

Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations

R&D

Clinician contemplating a tablet and protocols for CT design

Navigating the new ICH E6 (R3): Key changes for sponsors

These new regulations for running clinical trials in the UK will be a legal requirement from 28th April 2026.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

pharmaphorum podcast Episode 239, Dr Jorg Schuttrumpf

Shaping the future of immunodeficiency care, with Dr Jörg Sc...

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

R&D

pharmaphorum podcast Episode 235, Markus Vossman, Illumina

On genomics, NGS, and doing much more good than bad, with Ma...

Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.

R&D

pharmaphorum podcast Episode 230, Benedict Cross, PhoreMost

Harnessing the cell's own degradation machinery, with Benedi...

Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.

Video

R&D

The long-delayed promise of the microbiome, with Sam Possemi...

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

R&D

Allogeneic cell therapy isn’t dead, with Brian Culley

Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.

R&D

Interview at JPM26 with Adrian Woolfson and Kaihang Wang from Genyro

DNA as a programmable language, with Adrian Woolfson and Kai...

A new technology just announced this weekend in a paper in Nature could have a radical impact on how gene assembly is carried out.

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

Event

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

R&D

Partner Content

5th mRNA-Based Therapeutics Summit Europe

The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines

R&D

Partner Content

10th Tumor Models Summit San Francisco

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity

Partner Content

The Pharmaceutical Manufacturing and Packaging Congress (PHA...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2026 unites professionals to discuss the most recent trends of industry in Amsterdam

R&D

Partner Content

5th mRNA-Based Therapeutics Summit Europe

The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines

R&D

Partner Content

10th Tumor Models Summit San Francisco

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks